Failure to Satisfy Listing Rule Form 8 K

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On November 21, 2024, Stryve Foods, Inc. (the "Company") received a deficiency letter from the Nasdaq Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's Class A common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) ("Rule 5550(a)(2)"). The Nasdaq deficiency letter has no immediate effect on the listing of the Company's Class A common stock, and its Class A common stock will continue to trade on The Nasdaq Capital Market under the symbol "SNAX" at this time.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been given 180 calendar days, or until May 20, 2025, to regain compliance with Rule 5550(a)(2). If at any time before May 20, 2025, the bid price of the Company's Class A common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company may be back into compliance.

If the Company does not regain compliance with Rule 5550(a)(2) by May 20, 2025, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to provide written notice to Nasdaq of its intent to cure the deficiency during the second compliance period.

The Company intends to actively monitor the closing bid price for its Class A common stock and will consider available options to resolve the deficiency and regain compliance with Rule 5550(a)(2), including a potential reverse stock split. The deficiency letter had no impact on the Company's previously announced November 26, 2024 hearing before a Nasdaq Hearing Panel, at which the Company will present its plan of compliance regarding stockholders' equity compliance.

There can be no assurance that the Company will be able to regain compliance with the Minimum Stockholders' Equity Rule or will otherwise be in compliance with other applicable Nasdaq listing rules or that the Company's appeal of the delisting determination will be successful.